Prognostic implications of estrogen receptor 1 and vascular endothelial growth factor A expression in primary gallbladder carcinoma

AIM: To investigate the prognostic significance of estrogen receptor 1(ER1) and vascular endothelial growth factor A(VEGF-A) expression in primary gallbladder carcinoma(GBC) to identify new prognostic markers for this malignancy.METHODS: Using immunohistochemistry, we investigated ER1 and VEGF-A expression in 78 GBC and 78 cholelithiasis(CS) tissues. The results were correlated with clinicopathological features. Univariate and multivariate analyses were performed to evaluate the relationship between ER1 and VEGF-A expression and patients' prognosis. Further Kaplan-Meier survival analysis was also performed. RESULTS: ER1 and VEGF-A expression was significantly higher in GBC compared with CS(47/78 vs 28/78, P < 0.05; 51/78 vs 33/78, P < 0.05). ER1 expression was correlated with gender(P < 0.05) and VEGF-A expression was correlated with tumor differentiation in GBC patients(P < 0.05). In univariate analysis, age and tumor node metastasis(TNM) stage were factors associated with GBC prognosis(P < 0.05). Although there was no statistical difference between the expression of ER1 or VEGF-A and overall survival, the high expression of ER1 combined with VEGF-A predicted a poor prognosis for GBC patients(16.30 ± 1.87 vs 24.97 ± 2.09, log-rank P < 0.05). In multivariate analysis, combined expression of ER1 and VEGF-A and TNM stage were independent prognostic factors for GBC patients(P < 0.05).CONCLUSION: Combined expression of ER1 and VEGF-A is a potential prognostic marker for GBC patients. Clinical detection of ER1 and VEGF-A in surgically resected GBC tissues would provide animportant reference for decision-making of postoperative treatment programs.

Comprehensive Analysis of Estrogen Receptor 1 Dysregulation in Liver Hepatocellular Carcinoma: Implications for Prognosis and Therapeutic Targeting - A Secondary Publication

The study investigates the expression pattern and regulatory mechanisms of estrogen receptor 1 (ESR1) in liver hepatocellular carcinoma (LIHC) through comprehensive bioinformatics analysis. Utilizing UALCAN and GEPIA2 databases, significant down-regulation of ESR1 expression is observed in LIHC samples compared to normal controls, indicating its potential role in tumor progression. Further analysis reveals consistent down-regulation across different clinical variables including patient age, gender, race, and various stages of LIHC, affirming the regulatory role of ESR1 in tumor development and progression. Additionally, promoter methylation analysis demonstrates hypermethylation of ESR1 in LIHC samples, negatively correlating with its expression. This association persists across different clinical parameters, emphasizing the inverse relationship between ESR1 methylation and expression levels. Survival analysis indicates that up- regulation of ESR1 is associated with better overall survival, suggesting its potential as a prognostic biomarker in LIHC. Furthermore, genetic mutation analysis using cBioPortal reveals a spectrum of alterations in ESR1, including amplification, missense mutation, deep deletion, splice mutation, and truncating mutation, highlighting the genetic complexity of ESR1 in LIHC. These findings collectively contribute to a deeper understanding of ESR1 dysregulation in LIHC and its clinical implications as a potential therapeutic target and prognostic marker.

槲皮素通过雌激素受体下调长非编码RNA MALAT-1并发挥抗乳腺癌的作用机制

目的探索槲皮素抑制乳腺癌细胞恶性生物学行为的分子机制。方法以乳腺癌细胞系MCF-7和MB231作为研究对象,用慢病毒LV-ERα、LV-MALAT-1转染乳腺癌MB231细胞和MCF7细胞,RT-qPCR检测MALAT-1表达,Western blot检测肿瘤细胞中ERα蛋白表达,CCK-8细胞实验、平板克隆形成实验检测细胞增殖能力,PI染色法检测细胞周期,通过mRFP-GFP-LC3荧光双标腺病毒转染检测自噬水平,观察槲皮素和雌二醇对乳腺癌细胞增殖能力的影响。结果17β-雌二醇(E2)可以促进乳腺癌细胞MCF-7的增殖,而5μmol·L^(-1)槲皮素可以明显逆转E2对增殖的促进作用(P<0.05)。槲皮素对不表达雌激素受体α(estrogen receptor-α,ERα)的乳腺癌细胞MB231不表现抑制作用;而过表达ERα后,槲皮素则抑制了E2对MB231-ERα的促进作用。同时槲皮素可以抑制E2激活的MALAT-1表达;并且其抑制作用被过表达MALAT-1所逆转,包括细胞增殖,细胞周期进展以及克隆形成能力。结论槲皮素依赖于ERα的表达对乳腺癌的增殖等恶性行为起抑制作用,并且很可能是通过抑制MALAT-1的表达来发挥作用。

Inokosterone Is a Potential Drug Target of Estrogen Receptor 1 in Rheumatoid Arthritis Patients:Analysis from Active Ingredient of Cyathula Officinalis

Objective:To elucidate the active compounds and the molecular mechanism of Cyathula Off/c/na//s as a drug treatment for rheumatoid arthritis(RA).Methods:The target genes of active ingredients from Cyathula Officinalis were obtained from bioinformatics analysis tool for the molecular mechanism of traditional Chinese medicine.The protein-protein interaction between the target genes were analyzed using STRING and Genemania.The transcriptome of RA patients compared to healthy people(GSE121894)were analyzed using R program package Limma.The relative expression of the target genes was obtained from the RNA-seq datasets.The molecular docking analyses were processed based on the molecular model of estrogen receptor 1(ESR1)binding with estradiol(PDB ID:1A52).The binding details were analyzed by SYBYL.Results:Inokosterone,ecdysterone,and cyaterone were the 3 active ingredients from Cyathula Officinalis that bind to target genes.Of all the significantly changed genes from RA patients,ESR1,ADORA1,and ANXA1 were significantly increased in mRNA samples of RA patients.Conclusion:ESR1,the transcription factor that binds inokosterone in the molecular binding analysis,is the target protein of Cyathula Officinalis.

Molecular mechanism of endocrine-disruptive effects induced by Bisphenol A:The role of transmembrane G-protein estrogen receptor 1 and integrin αvβ3

Bisphenol A(BPA) is one of the highest volume industrial products worldwide and has been widely used to make various products as the intermediates of polycarbonate plastics and epoxy resins.Inevitably, general population has been widely exposed to BPA due to extensive use of BPAcontaining products. BPA has similar chemical structure with the natural estrogen and has been shown to induce a variety of estrogen-like endocrine effects on organism in vivo or in vitro. High doses of BPA tend to act as antagonist of estrogen receptors(ERs) by directly regulating the genomic transcription. However, BPA at environmentally relevant low-dose always disrupt the biological function via a non-genomic manner mediated by membrane receptors, rather than ERs. Although some studies had investigated the non-genomic effects of low-dose BPA, the exact molecular mechanism still remains unclear. Recently, we found that membrane G protein-coupled estrogen receptor 1 and integrin αvβ3 and its relative signal pathways participate in the induction of male germ cell proliferation and thyroid transcription disruption by the low-dose BPA. A profound understanding for the mechanism of action of the environmentally relevant BPA exposure not only contributes to objectively evaluate and predict the potential influence to human health, but also provides theoretical basis and methodological support for assessing health effects trigged by other estrogen-like environmental endocrine disruptors. Based mainly on our recent findings, this review outlines the research progress of molecular mechanism on endocrine disrupting effects of environmental low-dose BPA, existing problems and some consideration for future studies.

Estrogen affects neuropathic pain through upregulating N-methyl-D-aspartate acid receptor 1 expression in the dorsal root ganglion of rats

Estrogen affects the generation and transmission of neuropathic pain,but the specific regulatory mechanism is still unclear.Activation of the N-methyl-D-aspartate acid receptor 1（NMDAR1） plays an important role in the production and maintenance of hyperalgesia and allodynia.The present study was conducted to determine whether a relationship exists between estrogen and NMDAR1 in peripheral nerve pain.A chronic sciatic nerve constriction injury model of chronic neuropathic pain was established in rats.These rats were then subcutaneously injected with 17β-estradiol,the NMDAR1 antagonist D（-）-2-amino-5-phosphonopentanoic acid（AP-5）,or both once daily for 15 days.Compared with injured drug na？ve rats,rats with chronic sciatic nerve injury that were administered estradiol showed a lower paw withdrawal mechanical threshold and a shorter paw withdrawal thermal latency,indicating increased sensitivity to mechanical and thermal pain.Estrogen administration was also associated with increased expression of NMDAR1 immunoreactivity（as assessed by immunohistochemistry） and protein（as determined by western blot assay） in spinal dorsal root ganglia.This 17β-estradiol-induced increase in NMDAR1 expression was blocked by co-administration with AP-5,whereas AP-5 alone did not affect NMDAR1 expression.These results suggest that 17β-estradiol administration significantly reduced mechanical and thermal pain thresholds in rats with chronic constriction of the sciatic nerve,and that the mechanism for this increased sensitivity may be related to the upregulation of NMDAR1 expression in dorsal root ganglia.

血清可溶性神经调节蛋白-1、G蛋白偶联雌激素受体-1在急性胰腺炎患者病情及预后评估中临床价值研究

目的探讨血清可溶性神经调节蛋白-1(sNRG-1)、G蛋白偶联雌激素受体-1(GPER-1)在急性胰腺炎(AP)患者病情及预后评估中的临床价值。方法选取自2019年6月至2022年6月邯郸市第一医院收治的106例AP患者为研究对象,根据AP病情严重程度分为轻症组(n=49)、中重症组(n=36)及重症组(n=21);根据预后生存情况分为存活组(n=83)与死亡组(n=23)。采用酶联免疫吸附法检测血清sNRG-1、GPER-1水平。采用受试者工作特性(ROC)曲线评估血清sNRG-1、GPER-1及两者联合检测对AP患者预后的评估价值。采用多因素Logistic回归分析探讨AP患者预后影响因素。结果中重症组、重症组患者血清sNRG-1水平低于轻症组,且重症组低于中重症组;中重症组、重症组患者血清GPER-1水平高于轻症组,且重症组高于中重症组,差异均有统计学意义(P<0.05)。存活组与死亡组病情严重程度、入院急性生理与慢性健康评分(APACHEⅡ)、白细胞计数、C反应蛋白、血肌酐、乳酸脱氢酶、血淀粉酶、血脂肪酶、sNRG-1、GPER-1比较,差异有统计学意义(P<0.05)。APACHEⅡ评分≥12分、sNRG-1≤17.74 pg/ml、GPER-1≥4.82 pg/ml是影响AP患者预后的独立危险因素(P<0.05)。血清sNRG-1、GPER-1预测AP患者预后的ROC曲线下面积分别为0.846、0.753。两者联合预测AP患者预后的ROC曲线下面积为0.917,特异度为86.75%,灵敏度为86.96%。结论血清sNRG-1低表达、GPER-1高表达与AP患者的病情严重程度及预后有关,有望作为评估AP患者预后的生物学指标。

G-protein-coupled estrogen receptor as a new therapeutic target for treating coronary artery disease

Coronary heart disease(CHD) continues to be the greatest mortality risk factor in the developed world. Estrogens are recognized to have great therapeutic potential to treat CHD and other cardiovascular diseases; however,a significant array of potentially debilitating side effects continues to limit their use. Moreover,recent clinical trials have indicated that long-term postmenopausal estrogen therapy may actually be detrimental to cardiovascular health. An exciting new development is the finding that the more recently discovered G-protein-coupled estrogen receptor(GPER) is expressed in coronary arteries-both in coronary endothelium and in smooth muscle within the vascular wall. Accumulating evidence indicates that GPER activation dilates coronary arteries and can also inhibit the prolif-eration and migration of coronary smooth muscle cells. Thus,selective GPER activation has the potential to increase coronary blood flow and possibly limit the debilitating consequences of coronary atherosclerotic disease. This review will highlight what is currently known regarding the impact of GPER activation on coronary arteries and the potential signaling mechanisms stimulated by GPER agonists in these vessels. A thorough understanding of GPER function in coronary arteries may promote the development of new therapies that would help alleviate CHD,while limiting the potentially dangerous side effects of estrogen therapy.

High mobility group protein 1: A collaborator in nucleosome dynamics and estrogen-responsive gene expression

High mobility group protein 1(HMGB1) is a multifunctional protein that interacts with DNA and chromatin to influence the regulation of transcription, DNA replication and repair and recombination. We show that HMGB1 alters the structure and stability of the canonical nucleosome(N) in a nonenzymatic,adenosine triphosphate-independent manner. As a result, the canonical nucleosome is converted to two stable, physically distinct nucleosome conformers. Although estrogen receptor(ER) does not bind to its consensus estrogen response element within a nucleosome, HMGB1 restructures the nucleosome to facilitate strong ER binding. The isolated HMGB1-restructured nucleosomes(N' and N'') remain stable and exhibit a number of characteristics that are distinctly different from the canonical nucleosome. These findings complement previous studies that showed(1) HMGB1 stimulates in vivo transcriptional activation at estrogen response elements and(2) knock down of HMGB1 expression by siR NA precipitously reduced transcriptional activation. The findings indicate that a major facet of the mechanism of HMGB1 action involves a restructuring of aspects of the nucleosome that appear to relax structural constraints within the nucleosome. The findings are extended to reveal the differences between ER and the other steroid hormone receptors. A working proposal outlines mechanisms that highlight the multiple facets that HMGB1 may utilize in restructuring the nucleosome.

G蛋白偶联雌激素受体1在骨代谢中作用的研究进展

G蛋白偶联雌激素受体1(G protein-coupled estrogen receptor 1,GPER1)是一种雌激素的膜受体,其通过快速的细胞多效应作用引发下游反应,对成骨细胞的增殖分化产生影响。因此,GPER1在雌激素介导的骨代谢中有着重要作用。本文对GPER1在骨代谢中的作用作了简要总结,包括GPER1在青春期参与骨生长的过程,在机体不同雌激素水平下的骨代谢中体现出的不同功能,以及其与其他受体共同作用参与了骨代谢。

Quantified gene expression levels for phase Ⅰ/Ⅱ metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk （UK） versus low-risk （India）for adenocarcinoma at this organ site：a preliminary study

Risk of clinically significant prostate adenocarcinoma （CAP） varies worldwide,although there is a uniform prevalence of latent disease. A hormone-responsive tissue,the prostate possesses the metabolizing capacity to biotransform a variety of environmental procarcinogens or endogenous hormones. Whether such metabolizing capacity or estrogen receptor （ER） status underlies these demographic differences in susceptibility to CaP remains unclear. With appropriate ethical permission,verified-benign tissues were obtained following transurethral resection of the prostate from a high-risk region （n = 12 UK-resident Caucasians） and a typically low-risk region （n = 14 India-resident Asians）. Quantitative gene expression analysis was employed for cytochrome P450 （CYP）1B1,N-acetyltransferase （NAT）1,NAT2,catechol-O-methyl transferase （ COMT）,sulfotransferase （ SULT） 1A1,ERα,ERβ and aromatase （CYP To quantify the presence or absence of CYP1B1,ERα or ERβ,and to identify ther in situ localization,immunohistochemistry was carried out. The two cohorts had reasonably well-matched serum levels of prostate-specific antigen or hormones. Expression levels for the candidate genes investigated were similar.However,clear differences in protein levels for CYP1B1 and ERβ were noted. Staining for CYP1B1 tended to be nuclear-associated in the basal glandular epithelial cells,and in UK-resident Caucasian tissues was present at a higher （P = 0.006） level compared with that from India-resident Asians. In contrast,a higher level of positive ERβ staining was noted in prostates from India-resident Asians. These study findings point to differences in metabolizing capacity and ER status in benign prostate tissues that might modulate susceptibility to the emergence of clinically significant CaP in demographically distinct populations.

乳腺癌组织中COL11A1表达与ER、PR、HER-2和Ki-67的相关性分析

目的探讨乳腺癌组织中Ⅺ型胶原α1(COL11A1)表达与雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体-2(HER-2)和Ki-67的关系。方法采用免疫组化EnVision两步法检测18例乳腺纤维腺瘤组织和120例乳腺癌组织(36例原位癌组织、84例浸润性癌组织)中COL11A1的表达,同时对乳腺癌组织进行ER、PR、HER-2和Ki-67免疫组化检测,对HER-2(2+)进行荧光原位杂交检测;分析COL11A1表达与乳腺癌临床病理特征和多种免疫标记(ER、PR、HER-2和Ki-67)的关系。结果免疫组化结果显示COL11A1主要表达于乳腺癌细胞中。在纤维腺瘤组织中COL11A1表达呈弱阳性。COL11A1在原位癌中表达高于浸润性乳腺癌(P<0.05)。COL11A1表达与乳腺癌患者的年龄、部位、肿块大小和淋巴结转移无关(P>0.05),而中、高分化组织的COL11A1表达水平高于低分化组织,差异有统计学意义(P<0.05)。进一步分析COL11A1与乳腺癌其他免疫标记间的相关性发现,在Ki-67高表达组织中COL11A1低表达的比例更高,差异有统计学意义(P<0.05),而其他3种标记与COL11A1的表达无关(P>0.05)。结论COL11A1在浸润性乳腺癌中表达较原位癌低,在低分化乳腺癌中表达水平较中高分化更低,且与Ki-67表达有关,提示COL11Al表达在乳腺癌发生发展过程中是动态变化的,为乳腺癌的诊断治疗提供潜在标记物。

MTA-1、HIF-1α、ER、PR在子宫内膜癌临床特征上的表达差异及相关性分析

目的 探究肿瘤转移相关基因-1(MTA-1)、缺氧诱导因子-1α(HIF-1α)、雌激素受体(ER)、孕激素受体(PR)在子宫内膜癌(EC)临床特征上的表达差异及相关性。方法 选取2017年6月至2020年6月保定市妇幼保健院收治的62例EC患者作为研究对象,设为研究组,获取其的病理标本。另选取同期于保定市妇幼保健院进行治疗的118例子宫肌瘤、子宫腺肌症、子宫内膜息肉等患者设为对照组,均行子宫全切术治疗并获取子宫内膜组织标本,其中56例为子宫内膜不典型增生患者,设为对照1组,60例为正常子宫内膜患者,设为对照2组。对纳入标本进行免疫组化检测,观察并比较MTA-1、HIF-1α、ER、PR阳性表达情况,分析MTA-1、HIF-1α、ER、PR在EC临床特征上的表达差异及相关性。结果 研究组MTA-1和HIF-1α阳性率高于对照组,对照2组高于对照1组(P<0.05);研究组ER和PR阳性率低于对照组,对照2组低于对照1组(P<0.05);EC患者在不同肌肉浸润程度、不同国际妇产科联盟(FIGO)分期、不同组织学分级及有无淋巴结转移中MTA-1、HIF-1α、ER、PR阳性率表达情况比较,差异具有统计学意义(P<0.05);MTA-1、HIF-1α阳性表达与肌肉浸润程度、FIGO分期及淋巴结转移呈正相关(r=0.316、0.254、0.347,0.376、0.412、0.269,P<0.05),与组织学分级呈负相关(r=-0.562、-0.447,P<0.05),ER、PR阳性表达与上述4个临床特征均呈负相关(r=-0.485、-0.226、-0.634、-0.215,-0.313、-0.664、-0.415、-0.532,P<0.05)。结论 MTA-1、HIF-1α在EC中的阳性表达率升高,ER和PR阳性表达率降低,MTA-1、HIF-1α、ER、PR与临床特征关系密切,具有一定相关性,上述指标的检测可对临床诊断和治疗EC患者提供有效依据。

G蛋白偶联雌激素受体1、表皮生长因子受体和趋化因子受体1在甲状腺乳头状癌中的表达及意义

目的探讨G蛋白偶联雌激素受体1(G protein-coupled estrogen receptor1,GPER1)、表皮生长因子受体(epidermal growth factor receptor,EGFR)和趋化因子受体1(chemokine receptor1,CXCR1)在甲状腺乳头状癌(papillary thyroid carcinoma,PTC)组织中的表达及意义。方法甲状腺乳头状癌68例、结节性甲状腺肿42例,采用免疫组织化学S-P法检测GPER1、EGFR和CXCR1的表达,分析其与患者临床病理特征的关系,以及三者间表达的相关性。结果在PTC组织中,GPER1、EGFR和CXCR1的表达阳性率分别为76.5%、66.2%、64.7%,明显高于结节性甲状腺肿组的21.4%、16.7%和11.9%(P<0.01);GPER1、EGFR和CXCR1在PTC中的表达与颈部淋巴结转移相关(P<0.05),而与其他临床病理特征(年龄、性别、肿瘤大小及TNM分期)无相关性(P>0.05);在PTC及PTC淋巴转移癌组织中,GPER1与EGFR的表达呈显著正相关(r=0.262,P=0.031;r=0.542,P=0.002)、GPER1与CXCR1的表达也呈显著正相关(r=0.276,P=0.025;r=0.483,P=0.006)。结论 GPER1、EGFR和CXCR1的两两共表达与PTC的发生、发展密切相关,三者间可能存在一种相互作用。

雌激素受体1基因多态性与不明原因复发性流产关系

目的:探究雌激素受体1(ESR1)基因多态性与不明原因复发性自然流产(URSA)关系。方法:选取本院88例URSA患者为URSA组,70例正常者为对照组,采用聚合酶链式反应-限制性片段多态性法检测外周血ESR1基因rs22234693、rs9340799、rs2046210位点多态性,酶联免疫吸附法检测血清雌二醇(E2)水平,化学发光法检测促卵泡刺激素(FSH)水平;胶体金法检测血清促黄体生成素(LH)水平,Hardy-weinberg遗传平衡定律验证基因型频率;logistic回归分析ESR1基因型与URSA发生风险关系;分析各位点基因型与激素水平关系。结果:URSA组FSH水平高于对照组,E2、LH水平低于对照组(P<0.05)。两组ESR1基因rs22234693、rs9340799、rs2046210位点基因频率符合Hardy-Weinberg遗传平衡定律。rs22234693位点T等位基因频率、rs9340799位点G等位基因频率、rs2046210位点T等位基因频率均高于对照组(P<0.05)。rs22234693、rs9340799、rs2046210位点突变型者血清E2、LH水平低于对照组(P<0.05)。rs22234693 TT和TC基因携带者发生URSA风险的相对危险度分别为CC等位基因的1.756倍和2.432倍,rs9340799 GG、AG基因携带者的发生URSA风险的相对危险度分别为AA等位基因的1.237倍和1.746倍,rs2046210 TT和TC基因携带者的发生URSA风险的相对危险度分别为CC等位基因的1.354倍和1.824倍。结论:ESR1基因rs22234693、rs9340799、rs2046210位点多态性与URSA发生有关,rs22234693位点C→T突变、rs9340799 A→G突变、rs2046210 C→T突变可增加URSA的发病风险。

ESR1基因多态性与膝骨关节炎患病风险的相关性研究

目的研究雌激素受体α(estrogen receptor 1,ESR1)基因多态性对膝骨关节炎(knee osteoarthritis,KOA)患病风险的相关性。方法选择我院2017年12月至2019年4月收治的KOA患者87例作为研究组,其中男61例,女26例;年龄42~80岁,平均(62.15±8.02)岁。同期在我院健康体检者87例作为对照组,其中男60例,女27例;年龄40~79岁,平均(63.47±7.93)岁。采用聚合酶链式反应-限制性片段长度多态性法检测ESR1基因Xbal、PvuⅡ的单核苷酸多态性(single nucleotide polymorphism,SNP),比较两组ESR1基因Xbal、PvuⅡ位点的基因型和等位基因分布频率,采用非条件logistic回归分析ESR1基因多态性与膝骨关节炎之间的相关性。结果ESR1基因聚合酶链式反应(polymerase chain reaction,PCR)产物经限制性内切酶Xbal消化可形成AA、AG、GG基因型,PCR产物经限制性内切酶PvuⅡ消化可形成TT、TC、CC基因型。研究组ESR1基因Xbal位点的AA、AG、GG基因型频率较对照组差异有统计学意义(P<0.05),研究组ESR1基因PvuⅡ位点的TT、TC、CC基因型频率较对照组差异有统计学意义(P<0.05)。ESR1基因Xbal位点的AG基因型与KOA高风险发病率显著相关(P<0.05),ESR1基因PvuⅡ位点的TC基因型与KOA高风险发病率显著相关(P<0.05)。CA单体型在研究组中分布频率显著高于对照组(P<0.05)。单体型CA与KOA高风险发病率显著相关(P<0.05)。结论ESR1基因多态性与膝骨关节炎发病有一定联系,ESR1基因突变可能会增加膝骨关节炎患病风险。该研究结果有助于阐明膝骨关节炎分子遗传学机制,为在基因水平上预测个体发病风险提供一定参考依据。

基于网络药理学和分子对接的白藜芦醇治疗口腔鳞状细胞癌的机制研究

目的通过网络药理学及分子对接等生物学信息方法,探讨白藜芦醇治疗口腔鳞状细胞癌(oral squamous cell carcinoma,OSCC)的分子机制,为白藜芦醇治疗OSCC的临床应用提供参考。方法利用Swiss Target Prediction(http://www.swisstargetprediction.ch)、SEA数据库(http://sea.bkslab.org)、Pharm mapper数据库(http://lilab-ecust.cn)检索获得白藜芦醇的相关靶点,以DISGENET(www.disgenet.org)、OMIM(https://omim.org)、GeneCards(https://www.genecards.org)数据库筛选OSCC疾病靶点,取药物与疾病靶点的交集,再采用Cytoscape 3.7.2软件构建“药物-疾病-靶点-通路”网络,String数据库构建靶蛋白相互作用网络,采用DAVID数据库对关键蛋白进行富集分析,最后通过AutoDock及PyMOL对关键蛋白进行分子对接验证,结合富集分析和分子对接结果预测白藜芦醇治疗OSCC可能的分子作用机制;细胞水平采用Western blot检测不同浓度(50、100μmol/L)白藜芦醇对OSCC细胞株HSC-3细胞Src酪氨酸激酶(Src tyro-sine kinase,SRC)、表皮生长因子受体(epidermal growth factor receptor,EGFR)、雌激素受体基因1(estrogen receptor gene 1,ESR1)及磷脂酰肌醇三激酶/蛋白激酶B(phosphatidylinositol 3 kinase/protein kinase B,PI3K/AKT)信号通路蛋白表达的影响。结果数据库得到白藜芦醇药物靶点243个,OSCC疾病靶点6094个,将药物与疾病的靶点进行交集获得116个潜在靶点,潜在靶点主要集中参与体内蛋白质自磷酸化、肽基酪氨酸磷酸化、跨膜受体蛋白酪氨酸激酶信号通路、RNA聚合酶Ⅱ启动子转录的正调控等生物过程,干预PI3K/AKT信号通路发挥抗OSCC的作用。分子对接结果表明白藜芦醇与EGFR、ESR1、SRC等OSCC关键靶点具有较好的结合活性。细胞实验结果表明,白藜芦醇药物干预以剂量依赖的方式抑制了HSC-3细胞中SRC、EGFR、ESR1及p-PI3K和p-AKT的蛋白表达。结论白藜芦醇对OSCC细胞SRC、EGFR、ESR1、p-PI3K、p-AKT靶点具有抑制作用。

hERR1在乳腺癌中的表达及其对芳香族化酶表达的调控

目的 了解hERR1在乳腺癌及癌旁组织中的表达情况 ,以及它对芳香族化酶基因表达的调节作用。方法 收集乳腺癌患者的临床标本 ,应用RT PCR法 ,研究癌组织及相应的癌旁组织中hERR1的表达情况 ;采用瞬时转染和CAT活性分析的方法 ,研究hERR1对芳香族化酶基因表达的调节。结果 hERR1在癌组织中的表达明显高于相应的癌旁组织 (16 2 6例 ) ;hERR1以剂量依赖方式促进芳香族化酶启动子Ⅰ 3活性。结论 hERR1在体内可能起到促进乳腺癌生长的作用。

雌激素受体α、雌激素受体β、激活蛋白1、血管内皮生长因子在大鼠子宫内膜异位症模型中的表达及意义

目的探讨雌激素受体α(ERα)、雌激素受体β(ERβ)、激活蛋白1(AP-1)、血管内皮生长因子(VEGF)在大鼠子宫内膜异位症(EMs)模型中的表达及意义。方法采用皮下种植法建立大鼠EMs模型,选取建模成功的28只大鼠为模型组(n=28),观察大鼠EMs模型在位内膜及异位病灶的组织病理学改变,并通过免疫组织化学法检测对照组子宫内膜、模型组在位子宫内膜和异位病灶ERα、ERβ、AP-1、VEGF的表达情况。结果 1大鼠EMs模型在位内膜及异位病灶腺体、间质血管明显增加;2大鼠EMs模型的异位病灶与对照组子宫内膜间ERα阳性率比较,差异无统计学意义(P=0.107),而其在位内膜中的表达较对照组比较,差异有统计学意义(P<0.01)。ERβ、AP-1(c-jun)蛋白、VEGF在模型组在位内膜及异位病灶中阳性率与对照组比较,差异有统计学意义(P<0.01),但其在位内膜及异位病灶中的表达比较,差异无统计学意义。结论大鼠EMs模型在位内膜中ERα和ERβ均高表达,异位病灶中则仅表现为ERβ高表达,同时上调c-jun,VEGF的表达,ERβ可能在EMs的发生发展中起到较ERα更为重要的作用。

内分泌治疗激素受体阳性乳腺癌的效果及其与ESR1基因位点的关系

目的研究内分泌治疗激素受体阳性乳腺癌的效果及其与雌激素受体1基因(ESR1)单核苷酸多态性位点(rs2077647和rs3798759)的关系。方法选择2014年1月—2018年12月于江苏省常熟市第五人民医院收治的86例激素受体阳性乳腺癌患者为研究对象,均接受内分泌治疗,并接受ESR1单核苷酸多态性位点(rs2077647和rs3798759)检测。分析内分泌治疗后短期疗效,并观察其与ESR1单核苷酸多态性位点的关系。结果86例患者内分泌治疗后完全缓解、部分缓解、疾病稳定共45例,均归入ETR组;疾病进展41例,归入ETNR组。ETR组rs2077647位点基因型为CC型者占比显著高于ETNR组(P<0.05),rs3798759位点基因型为TT型者占比显著低于ETNR组(P<0.05),且基因型为TG型者占比显著高于ETNR组(P<0.05)。ETR组rs2077647位点等位基因为C者占比显著高于ETNR组(P<0.05),rs3798759位点等位基因为G者占比显著高于ETNR组(P<0.05)。ESR1基因多态性是患者内分泌治疗效果的独立影响因素(P<0.05)。结论内分泌治疗激素受体阳性乳腺癌后疗效与ESR1单核苷酸多态性位点(rs2077647和rs3798759)密切相关。